Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eutilex, Zhejiang Enter Immuno-Oncology Partnership | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Eutilex, Zhejiang Enter Immuno-Oncology Partnership

Aims to advance Eutilex's antibody and anti-tumor T cell therapy development programs

By: Betsy Louda

, Contract Pharma

Eutilex Co. Ltd. has entered a strategic partnership with Zhejiang Huahai Pharmaceutical Ltd., both based in China, to accelerate Eutilex’s antibody and anti-tumor T cell therapy development programs.
 
Under the agreement, Huahai will take a $30 million equity stake in Eutilex and in return will receive an exclusive license to develop and commercialize EU-101, an antibody developed for cancer treatment.
 
Eutilex is eligible to receive milestone payments from Huahai for EU-101 approved immuno-oncology indications. The deal is also expected to further expand Eutilex’s global clinical trials on T cell therapies. Some patients with solid tumors or hematologic cancers who were treated with this therapy went into a period of remission that lasted as long as two-and-a-half years.
 
Dr. Byoung S. Kwon, Eutilex founder and chief executive officer, said, “Huahai is bringing strong technical, production and R&D skills to its partnership with us.”  
 
Dr. Baohua Chen, Huahai Chairman, added, “With multiple immune-oncology assets and compelling safety and efficacy data, Eutilex is a very attractive partner.” 
 
The agreement brings Huahai’s total investment in Eutilex from various sources to $58.7 million since the company’s founding in 2015. 
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics